Lexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Quarterly Sales of $13.73 Million

Brokerages predict that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will report $13.73 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Lexicon Pharmaceuticals’ earnings, with the highest sales estimate coming in at $15.48 million and the lowest estimate coming in at $10.51 million. Lexicon Pharmaceuticals posted sales of $33.05 million during the same quarter last year, which suggests a negative year over year growth rate of 58.5%. The firm is expected to issue its next quarterly earnings report on Thursday, February 28th.

According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full year sales of $58.16 million for the current fiscal year, with estimates ranging from $54.00 million to $61.29 million. For the next year, analysts anticipate that the company will report sales of $176.51 million, with estimates ranging from $86.90 million to $262.56 million. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.07. The company had revenue of $6.90 million for the quarter, compared to analyst estimates of $12.56 million. Lexicon Pharmaceuticals had a negative net margin of 168.23% and a negative return on equity of 1,247.65%. The firm’s revenue was down 74.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.29) EPS.

Several equities research analysts recently issued reports on LXRX shares. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, October 4th. ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 28th. Citigroup decreased their price target on shares of Lexicon Pharmaceuticals from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, November 2nd. Gabelli reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 2nd. Finally, Cowen reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 2nd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $25.25.

Institutional investors and hedge funds have recently bought and sold shares of the business. Tocqueville Asset Management L.P. bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter worth approximately $164,000. Dynamic Technology Lab Private Ltd bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter worth approximately $205,000. MetLife Investment Advisors LLC grew its holdings in Lexicon Pharmaceuticals by 49.8% during the 3rd quarter. MetLife Investment Advisors LLC now owns 35,705 shares of the biopharmaceutical company’s stock worth $381,000 after acquiring an additional 11,862 shares during the last quarter. Tekla Capital Management LLC bought a new stake in Lexicon Pharmaceuticals during the 3rd quarter worth approximately $747,000. Finally, GSA Capital Partners LLP grew its holdings in Lexicon Pharmaceuticals by 321.7% during the 3rd quarter. GSA Capital Partners LLP now owns 74,586 shares of the biopharmaceutical company’s stock worth $796,000 after acquiring an additional 56,900 shares during the last quarter.

Shares of Lexicon Pharmaceuticals stock traded down $0.50 during midday trading on Wednesday, hitting $7.44. 533,618 shares of the company traded hands, compared to its average volume of 386,282. The firm has a market capitalization of $858.00 million, a PE ratio of -5.86 and a beta of 0.75. The company has a current ratio of 2.90, a quick ratio of 2.83 and a debt-to-equity ratio of 8.85. Lexicon Pharmaceuticals has a 12 month low of $7.04 and a 12 month high of $13.97.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Recommended Story: Hedge Funds

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply